Third Pole Therapeutics Announces Global Commercialization Agreement with Chiesi Group for Its Tankless, Portable Inhaled Nitric Oxide (iNO) Delivery System

  April 8, 2020   Company Press Releases

Agreement Will Significantly Expand Patient Access to Therapeutic iNO Beyond the Existing $800M+ Global Hospital Market

Waltham, MA – April 8, 2020 – Third Pole Therapeutics, a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced it has entered into a global license, development and commercialization agreement with Chiesi Farmaceutici, an international research-focused pharmaceutical group (Chiesi Group).

>> Read More